MAPT and Alzheimer disease: The mechanistic approaches to development of AD therapies, with NPs carrying therapeutic agents, are: (a) the clearance of Aβ fibrils/aggregates; (b) the development of acetylcholinesterase inhibitors loaded NPs to ameliorate cholinergic system impairment; (c) the attenuation of neuroinflammation; (d) the attenuation of tau hyperphosphorylation; (e) the development of anti-Aβ peptide antibodies loaded on circulating NPs that initiate ‘the sink mechanism’, by removing the soluble Aβ peptides from the brain to the blood circulation.